Cargando…

Role of cancer ratio and other new parameters in the differential diagnosis of malignant pleural effusion

OBJECTIVES: We compared the diagnostic potential of cancer ratio (CR, serum lactate dehydrogenase [LDH]/pleural fluid adenosine deaminase [pfADA]), cancer ratio plus (CR plus, cancer ratio/pleural lymphocyte percentage), and age/pfADA ratio with pfADA in malignant pleural effusion. METHODS: Data fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Zenghua, Xu, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Faculdade de Medicina / USP 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050601/
https://www.ncbi.nlm.nih.gov/pubmed/33909825
http://dx.doi.org/10.6061/clinics/2021/e2515
_version_ 1783679611070054400
author Ren, Zenghua
Xu, Ling
author_facet Ren, Zenghua
Xu, Ling
author_sort Ren, Zenghua
collection PubMed
description OBJECTIVES: We compared the diagnostic potential of cancer ratio (CR, serum lactate dehydrogenase [LDH]/pleural fluid adenosine deaminase [pfADA]), cancer ratio plus (CR plus, cancer ratio/pleural lymphocyte percentage), and age/pfADA ratio with pfADA in malignant pleural effusion. METHODS: Data from 100 patients with malignant pleural effusion (MPE) and 119 patients with tuberculous pleural effusion (TPE) were retrospectively collected. PfADA, age/pfADA ratio, CR, and CR plus were compared between patients with MPE and those with TPE in two age groups (≤50 and >50 years). The best cut-off value was determined, and the diagnostic performance was evaluated according to the receiver operating characteristic curve. RESULTS: PfADA was statistically significantly lower while age/pfADA ratio, CR, and CR plus were significantly higher in the MPE group than in the TPE group in both age groups (p<0.05). For patients aged ≤50 years, the differential diagnostic value of pfADA for MPE was better than those of age/pfADA ratio, CR, and CR plus. At a cut-off value of 13.0 U/L, the sensitivity, specificity, and accuracy were 88.9%, 100.0%, and 98.9%, respectively. For patients aged >50 years, the diagnostic performance of CR plus was superior to those of pfADA, age/pfADA ratio, and CR. At a cut-off value of 22.6, the sensitivity, specificity, and accuracy of CR plus for the diagnosis of MPE were 86.8%, 84.6%, and 86.2%, respectively. CONCLUSIONS: The best parameter for diagnosing MPE was different for patients aged ≤50 years and >50 years. For patients aged >50 years, CR plus was a good parameter for the differential diagnosis of MPE. For patients aged ≤50 years, pfADA was better.
format Online
Article
Text
id pubmed-8050601
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Faculdade de Medicina / USP
record_format MEDLINE/PubMed
spelling pubmed-80506012021-04-16 Role of cancer ratio and other new parameters in the differential diagnosis of malignant pleural effusion Ren, Zenghua Xu, Ling Clinics (Sao Paulo) Original Article OBJECTIVES: We compared the diagnostic potential of cancer ratio (CR, serum lactate dehydrogenase [LDH]/pleural fluid adenosine deaminase [pfADA]), cancer ratio plus (CR plus, cancer ratio/pleural lymphocyte percentage), and age/pfADA ratio with pfADA in malignant pleural effusion. METHODS: Data from 100 patients with malignant pleural effusion (MPE) and 119 patients with tuberculous pleural effusion (TPE) were retrospectively collected. PfADA, age/pfADA ratio, CR, and CR plus were compared between patients with MPE and those with TPE in two age groups (≤50 and >50 years). The best cut-off value was determined, and the diagnostic performance was evaluated according to the receiver operating characteristic curve. RESULTS: PfADA was statistically significantly lower while age/pfADA ratio, CR, and CR plus were significantly higher in the MPE group than in the TPE group in both age groups (p<0.05). For patients aged ≤50 years, the differential diagnostic value of pfADA for MPE was better than those of age/pfADA ratio, CR, and CR plus. At a cut-off value of 13.0 U/L, the sensitivity, specificity, and accuracy were 88.9%, 100.0%, and 98.9%, respectively. For patients aged >50 years, the diagnostic performance of CR plus was superior to those of pfADA, age/pfADA ratio, and CR. At a cut-off value of 22.6, the sensitivity, specificity, and accuracy of CR plus for the diagnosis of MPE were 86.8%, 84.6%, and 86.2%, respectively. CONCLUSIONS: The best parameter for diagnosing MPE was different for patients aged ≤50 years and >50 years. For patients aged >50 years, CR plus was a good parameter for the differential diagnosis of MPE. For patients aged ≤50 years, pfADA was better. Faculdade de Medicina / USP 2021-04-16 2021 /pmc/articles/PMC8050601/ /pubmed/33909825 http://dx.doi.org/10.6061/clinics/2021/e2515 Text en Copyright © 2021 CLINICS https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.
spellingShingle Original Article
Ren, Zenghua
Xu, Ling
Role of cancer ratio and other new parameters in the differential diagnosis of malignant pleural effusion
title Role of cancer ratio and other new parameters in the differential diagnosis of malignant pleural effusion
title_full Role of cancer ratio and other new parameters in the differential diagnosis of malignant pleural effusion
title_fullStr Role of cancer ratio and other new parameters in the differential diagnosis of malignant pleural effusion
title_full_unstemmed Role of cancer ratio and other new parameters in the differential diagnosis of malignant pleural effusion
title_short Role of cancer ratio and other new parameters in the differential diagnosis of malignant pleural effusion
title_sort role of cancer ratio and other new parameters in the differential diagnosis of malignant pleural effusion
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050601/
https://www.ncbi.nlm.nih.gov/pubmed/33909825
http://dx.doi.org/10.6061/clinics/2021/e2515
work_keys_str_mv AT renzenghua roleofcancerratioandothernewparametersinthedifferentialdiagnosisofmalignantpleuraleffusion
AT xuling roleofcancerratioandothernewparametersinthedifferentialdiagnosisofmalignantpleuraleffusion